29-04-2025
ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Steve Seedhouse assumed coverage of ProQR Therapeutics (PRQR) with an Overweight rating and $8 price target ProQR is a leader in RNA editing and the initial biomarker data for its first program targeting bile acid transporter in Q4 will be an 'important catalyst,' the analyst tells investors in a research note. Cantor views the company as a 'pure play' on RNA editing.
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders' Hot Stocks on TipRanks >>
Read More on PRQR:
Disclaimer & DisclosureReport an Issue
ProQR Therapeutics initiated with an Outperform at Evercore ISI
ProQR Announces New CFO and CMO to Drive Growth
ProQR Therapeutics appoints Hom as CFO, Lopez as CMO
ProQR Therapeutics Advances RNA Editing Pipeline
ProQR's Axiomer Technology and AX-0810: A Promising Buy Rating with Increased Price Target
